Stay up to date with our latest news, financial reports and company updates.
Coegin Pharma is a Swedish biotechnology company developing cutting-edge innovations for hair growth and skin pigmentation. We plan to launch a hair growth product series by the end of 2025, followed by a skin pigmentation product in 2026. We’re listed on NGM Nordic SME and duallisted on Börse Stuttgart.
On this page, you’ll find press releases, financial reports, calendar, and shareholder information.
Why invest in Coegin Pharma?
1. Strong scientific foundation
Built on research from NTNU and collaborations with leading universities and partners.
2. Cutting-edge pipeline ready for market
Two proprietary peptides progressing rapidly, with Follicopeptide planned for launch late 2025.
3. Premium positioning in high-growth longevity markets
Addressing underserved needs in hair growth and skin pigmentation within the expanding global longevity trend.
4. Commercial focus and strategic partnerships
Driving efficient market entry through flexible collaborations to maximise reach and impact.
IR contact
